This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Resumen de acción HQ8F
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices for gastrointestinal therapeutic endoscopy.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Competidores de Apollo Endosurgery, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.10 |
| 52 Week High | US$9.64 |
| 52 Week Low | US$3.39 |
| Beta | 2.32 |
| 1 Month Change | -0.85% |
| 3 Month Change | -1.88% |
| 1 Year Change | 70.35% |
| 3 Year Change | 386.63% |
| 5 Year Change | 92.80% |
| Change since IPO | -49.11% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| HQ8F | DE Medical Equipment | Mercado DE | |
|---|---|---|---|
| 7D | 1.0% | -1.9% | -1.0% |
| 1Y | 70.3% | -10.8% | 2.0% |
Rentabilidad vs. Industria: HQ8F exceeded the German Medical Equipment industry which returned -7% over the past year.
Rentabilidad vs. Mercado: HQ8F exceeded the German Market which returned -8.6% over the past year.
Volatilidad de los precios
| HQ8F volatility | |
|---|---|
| HQ8F Average Weekly Movement | 1.4% |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Precio estable de las acciones: HQ8F has not had significant price volatility in the past 3 months.
Volatilidad a lo largo del tiempo: HQ8F's weekly volatility has decreased from 12% to 1% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2005 | 202 | Chas McKhann | www.apolloendo.com |
Resumen de fundamentos de Apollo Endosurgery, Inc.
| Estadísticas fundamentales de HQ8F | |
|---|---|
| Capitalización bursátil | €531.72m |
| Beneficios(TTM) | -€36.54m |
| Ingresos (TTM) | €70.49m |
7.5x
Ratio precio-ventas (PS)-14.6x
Ratio precio-beneficio (PE)¿Está HQ8F sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de HQ8F | |
|---|---|
| Ingresos | US$76.86m |
| Coste de los ingresos | US$34.43m |
| Beneficio bruto | US$42.43m |
| Otros gastos | US$82.27m |
| Beneficios | -US$39.84m |
Últimos beneficios comunicados
Dec 31, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.69 |
| Margen bruto | 55.20% |
| Margen de beneficio neto | -51.84% |
| Ratio deuda/patrimonio | 164.7% |
¿Cómo se ha desempeñado HQ8F a largo plazo?
Ver rendimiento histórico y comparativa